Geraldine O. Canny

Geraldine O. Canny

Auto-generated profile, based on publicly available information

Geraldine O. Canny

Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
GCGeraldine Canny
Geraldine Canny
OLOfer Levy
Ofer Levy
GFGlenn T. Furuta
Glenn T. Furuta
SNSailaja Narravula-Alipati
Sailaja Narravula-Alipati
RSRichard B. Sisson
Richard B. Sisson
SCSean P. Colgan
Sean P. Colgan
Epithelial cells which line mucosal surfaces are the first line of defense against bacterial invasion and infection. Recent studies have also indicated that epithelial cells contribute significantly to the orchestration of ongoing inflammatory processes. Here, we demonstrate that human epithelial cells express bactericidal/permeability-increasing protein (BPI), an antibacterial and endotoxin-neutralizing molecule previously associated with neutrophils. Moreover, we demonstrate that such BPI expression is transcriptionally regulated by analogs of endogenously occurring anti-inflammatory eicosanoids (aspirin-triggered lipoxins, ATLa). Initial studies to verify microarray analysis revealed that epithelial cells of wide origin (oral, pulmonary, and gastrointestinal mucosa) express BPI and each is similarly regulated by aspirin-triggered lipoxins. Studies aimed at localization of BPI revealed that such expression occurs on the cell surface of cultured epithelial cell lines and dominantly localizes to epithelia in human mucosal tissue. Functional studies employing a BPI-neutralizing anti-serum revealed that surface BPI blocks endotoxin-mediated signaling in epithelia and killsSalmonellatyphimurium. These studies identify a previously unappreciated “molecular shield” for protection of mucosal surfaces against Gram-negative bacteria and their endotoxin.

11 May 2007 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ECEric L. Campbell
Eric L. Campbell
NLNancy A. Louis
Nancy A. Louis
STSarah E. Tomassetti
Sarah E. Tomassetti
GCGeraldine O. Canny
Geraldine O. Canny
MAMakoto Arita
Makoto Arita
SCSean P. Colgan
Sean P. Colgan
Migration of neutrophils (PMN) across epithelia is a pathological hallmark of numerous muco‐sal diseases. Whereas lesions at mucosal surfaces are generally self‐limiting, endogenous mechanisms of resolution are incompletely understood. Previous studies revealed that resolvins directly act on PMN to attenuate transendothelial migration, less is known about the influence of resolvins on PMN‐epithelial interactions and whether they act on epithelia. We studied the dynamics of resolvin E1 (RvE1) actions on leukocyte transepithelial migration. PMN exposure to RvE1 or chemerin (peptide agonist of ChemR23) reduced trans‐epithelial migration in a concentration‐dependent manner. Conversely, activation of epithelial ChemR23 promoted apical clearance of PMN. A nonbiased screen of known PMN ligands expressed on epithelial cells in response to RvE1 revealed selective induction of CD55, an apically expressed antiadhesive molecule. CD55 promoter analysis demonstrated that both RvE1 and chemerin activate the CD55 promoter. Inhibition of CD55 by neutralizing antibody prevented RvE1‐depen‐dent augmentation of apical PMN clearance. Taken together these findings implicate a “two‐hit” model of inflammatory resolution, whereby activation of the PMN RvE1 receptor attenuates transepithelial migration and subsequent actions on the epithelium promote CD55‐dependent clearance of PMN across the epithelial cell surface promoting active inflammatory resolution.—Campbell, E. L., Louis, N. A., Tomassetti, S. E., Canny, G. O., Arita, M., Serhan, C. N., Colgan, S. P. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 21, 3162–3170 (2007)

1 August 2008 in Infection and Immunity
Verified
Journal Article
Closed access
GCGeraldine O. Canny
Geraldine O. Canny
BMBeth A. McCormick
Beth A. McCormick

5 July 2006 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
NLNancy A. Louis
Nancy A. Louis
KHKathryn E. Hamilton
Kathryn E. Hamilton
GCGeraldine Canny
Geraldine Canny
LSLaurie L. Shekels
Laurie L. Shekels
SHSamuel B. Ho
Samuel B. Ho
SCSean P. Colgan
Sean P. Colgan

29 September 2016 in Rheumatology
Verified
Journal Article
Closed access
DADeshire Alpizar-Rodriguez
Deshire Alpizar-Rodriguez
NPNicola Pluchino
Nicola Pluchino
GCGeraldine Canny
Geraldine Canny
CGCem Gabay
Cem Gabay
AFAxel Finckh
Axel Finckh
RA is the most common chronic systemic autoimmune disease, with a higher prevalence in women, suggesting female hormonal factors play a role in the development of the disease. However, many controversies still exist. The aim of this review was to appraise data from recent research concerning female hormonal factors and their association with RA disease development. The study of female hormonal factors is challenging because serum levels may differ throughout a woman's lifetime and interact with various environmental, immunological, genetic and endocrine factors influencing the development of autoimmunity. As some female hormonal factors may be potentially modifiable, understanding their impact on RA development is clinically relevant and may result in specific preventive interventions in high-risk populations.

1 November 2012 in Fertility and Sterility
Verified
Journal Article
Closed access
CPChiara Pellegrini
Chiara Pellegrini
IGIlaria Gori
Ilaria Gori
CAChahin Achtari
Chahin Achtari
DHDaniela Hornung
Daniela Hornung
ECEric Chardonnens
Eric Chardonnens
GCGeraldine O. Canny
Geraldine O. Canny